Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.65 |
| ▸ | HSP90AB1 | P08238 | 14/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848586 | 1.00 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1ERBB2MEN1SLC22A1 | |
| SCHEMBL27584535 | 0.86 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL4845548 | 0.85 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL4845541 | 0.85 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL4852703 | 0.84 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL4853114 | 0.83 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL4844123 | 0.82 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1ERBB2MEN1SLC22A1 | |
| SCHEMBL4850767 | 0.80 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1ERBB2MEN1SLC22A1 | |
| SCHEMBL4847099 | 0.80 | HSP90AA1 (0.89) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL4854173 | 0.79 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101928288-B | Small molecule compositions for binding to HSP90 | SLOAN KETTERING INST CANCER | 2013-09-11 | — | — | CN | disclosed |
| EP-1335920-B1 | COMPOSITIONS CONTAINING PURINE DERIVATIVES FOR BINDING TO HSP90 | SLOAN KETTERING INST CANCER (US) | 2013-04-03 | — | — | EP | disclosed |
| US-7439359-B2 | Small molecule compositions for binding to hsp90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1335920-A4 | SMALL MOLECULE COMPOSITIONS FOR BINDING TO HSP90 | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040102458-A1 | Small molecule compositions for binding to hsp90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-05-27 | — | — | US | disclosed |
| EP-1335920-A2 | SMALL MOLECULE COMPOSITIONS FOR BINDING TO HSP90 | Sloan-Kettering Institute For Cancer Research (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002036075-A2 | SMALL MOLECULE COMPOSITIONS FOR BINDING TO HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102458-A1 | Small molecule compositions for binding to hsp90 | HSP90AB1, ERBB2, HSP90AB2P | HSP90AA1 5/4885HSP90AB1 1/4885ERBB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.